`
`INFORMATION DISCLOSUREitingDate=| 2018-10-01
`
`ee
`
`STATEMENT BY APPLICANT |examinerName=f
`
`C00017177US01(MED-29176/U
`
`U.S. PATENTS
`
`
`
`Examiner|Cite|Patent Kind|Issue Date Nameof Patentee or Pages, Columns, Lines where Relevant
`
`
`
`Initial |Number|CodeNo. Applicant of cited Passagesor Relevant Figures Appear
`
`Document
`arene8807-07 [wiyborny
`ee
`
`P___[2__[sisaraa___|__|1993-03-09|Martha T, Pelensky TO——
`
`
`Ps__[s2eaero|__|1904-02-08___[Betz OO
`
`
`pe[02288|[7984-04-12 [wed ee
`
`
`P___[s__[sa05745|__|1904.08-26|zacouto TO——
`
`Pe_[ssoasis|__|19905-03____|[ Khur OO
`
`
`[7[saia7s0|[1904-06-07|tascombes ee
`
`
`[___[s__[sas0157|__|1995.08-21|Nroolas Goux TO——
`
`
`|____e_[saatoas__|__|1995.08.15|Thomas M. Masano OO
`
`pro[s4a2069|1908-08-23 [router ee
`
`>__fai_[saasei0|__|TO——1998-08-29 [University of Gneinnal
`
`
`
`|____[re[saessss|__|te8s-i7-27|Goddard OO
`
`Pfs[062806|[1967-00-02|Baxterint ee
`
`
`P14[5085402|__|1997-11-04|Goedeke TO——
`
`
`Pfs[seasons [_—(re97-11-11|Paul Machosky OO
`
`[fe[716400|[1988-02-10|Smith & Nephew Ine ee
`
`
`-__[a7_[sraaoai__|__|1998-04-28|Bene TO——
`Kenley OO
`Emerson ee
`c
`Regents ofthe UnversiyofGA| —SSSSSSSOSCSCSOC~*?r
`EO
`Baxter Int OO
`eS
`Antonio Baset ee
`eSee
`
`eSEe Roberts TO——
`
`[2a[soars|Ansiyn OO
`
`[2s[e02622|Holmst’om ee
`
`-[28_[eosesat|King TO——
`
`Per_farrar7e|Gambro AB OO
`
`ea[siviceo|Philip G. Lee ee
`
`-___[2a__[si7e0033|Medtronic TO——
`
`[a0[230059|Duin OO
`
`ai[ezaaoas|Maberg ee
`
`-___[a2[e257|Tre TO——
`-_____[as__[aszitor__|
`Holmstrom OO
`
`[aeYeast|Maberg ee
`[fas_[eseaz7a__| BenHaim TO——
`
`
`[a8[es00869|Orais Medical Corporation OO
`
`arYosaitaa|Gambro AB ee
`
`[___[ae_[essa7os|Mann TO——
`
`[a0[esss086|Maberg OO
`
`[ao[ase5525|Vasea In ee
`
`-___[ai__[esese7s|CHF Solutions Ihe TO——
`
`[aa[asaaz20|Connelly OO
`
`[aaos8a747|Tut E. Puskas ee
`
`[____[aa[eseezae|DSU Medioa TO——
`
`
`|____[#5_[eeoasee|__|2003-08-08|Fromherz OO
`
`pasYseri6a|[2009-09-30|Wong ee
`
`/[ar_[eose840|__|2009-72-28|Alin Medical AB TO——
`
`[as[ose7ecos|__[2004.07-13|Keren OO
`[faa[6095807|__|2004-02-24[osuede———SSCSC~SCS
`
`
`Pp[so_[aritase__[__[2004-08-28[BradleySCS.SSSCSCS
`
`iG
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/AMM/
`
`Page 1/5
`
`
`
`Receipt date: 11/09/2018
`
`INFORMATION DISCLOSUREitingDate=| 2018-10-01
`
`C00017177US01(MED-29176/U [siierraaia«2004-08-10dFSouionsing.~——OC—C—“‘—‘“‘idYSC“‘;SCSCCOCOC~CSCSCOCVCCCC‘<CX
`
`PpCi*'S2fota7e4|2004-11-09Taylor
`pC‘SFfosisigg|2004-11-16Wong
`
`
`PS«dSAsfeerezes|«2005-04-12—=—=«thompson——SSC~—~SCSC‘“‘SSSOTTTTTCC~CS
`PS«*dS[eeoosis—[Csdoosoto—C—C*dEWINNGC—“—~Cs*~iCSC“‘(C;‘;CTTTTTCCSC
`
`[SSC«*dS6—eaearez[|———=«d[2005-08-02—=S—S«[CHFSoutionsnc~—O—C—‘;~‘dCSC“‘;CSS*SSSSSCTTTTTTTTTTTC*d
`PS«*dS7__[eseor7a[ios1-01~—Ss—“‘iGraS—ssCSC~—<“~iSC“‘“‘S;SNSOOOOCCCCCOC..CC*‘dS
`
`
`PS«*dS8[7ozoass|Cs[p0ne0418Caters—SC—C“‘*‘“*S*=C‘iSCS‘“‘S)SSOOOOOOUUOOOOOOOOCOC‘(NTNCd
`PpC*dSSfor78io|2006-07-18Golda
`
`[feo[707630|—_—*f 2006-08-29fFrankAGothSCidSCOOCOCOCOSCOCOCOCSC“(3NC!C#®*S
`
`PpCi*dSY7128750|2006-10-31EndoartSAE
`pCi7153693|2006-12-26Tay
`
`«esfr208oe2[2007-04-24[Miche@C—“—*~—~*~‘“‘—‘~iTSC“‘C;CSSSSSCCCTTTTTTTTTC*d
`PCi*dSAeatz7za|2007-07-10[Karoo
`
`pCi“e76042|07-10-02——s|Polaschegg|—Ci‘“C‘CsCs‘“‘“‘CSC*d
`
`
`Pee[7siasee|| 2008-07-78Marke.Comet—SCidSCOCOCSCSOSOSOCSCSC“‘;STTTCC~™Y
`
`Pie|7azes7e|«2008-02-05——=—«é[PrescientMedicaling,|CCS
`pC*S7384543|2008-06-10|GambrolundiaAB|CCCidC
`PC*@9=‘raeziet|~——=«d2008-12-09=HSolutionsinc.~—SSSCSC~idSSC(SSSSSSCSCSCSCSCSCSCSCSCSCSCSCTTiC
`PpCi*dQs7566432|2009-07-28Wong
`pd575564|2009-08-18Childers|
`PSSC«d72=rsore0s|C*00st0-06in’SC—~—“—~C—s~sSC“‘(;SSWTCS
`PC«*d3‘veraest|Cs[zorooss09~——C*dMCCOWBESC—=~*~“‘“‘C®CNNNSCN#NCidS#YN’N’NNNNNNNNNNNNNNNNN’N’Ss“§“§-—s—S—SS—wY
`
`PCH7674237|2010-03-09[CHFSolutionsinc,|Ci‘CSCidC
`
`[rs[768e778«2070-08-30—=*dNxStageMedicaling.SSTSOOOOCOCOC™CSOOCC*;S
`pCi‘=7704se1|00-04-27Garde
`P7307|00-06-15Wong
`PS«d8—=ivsase|Cspotoor-i3sume—SSC—C“—*‘“—*S*é*dSC“‘SSOOOOOCOC~™COCCY
`
`
`PC«*d7a—‘[vvsesv2[|Cs(poroorigs—C‘dAMDDSSCOC“‘“‘CSNS;CON#N#NC‘dh;SAU’N’N’NNNNNNNNNNNNNN’N’N’Ssw“~-s—SS—S
`PSB7776001|2010-08-17|NxStageMedicalInc.|CCidC
`fai[r7re00s[ito-08-i7hidesC~dSC‘“‘CSOSCOCSCSCSCSCCOCOCSC“(NNNCL
`PpC*BRsf77ezio|2010-08-17,[Rosenbaum
`PCS794i|20-09-14Perry
`
`pea[reseas[ioto-ia-iaiPoaschegg——SC—~—“—~—“‘“‘dYSC“‘(CSTCCS
`PoC*'S67214TotoChiiders
`
`pCi*BG9OIB7E|2011-03-08BaxterInt,|
`
`PS=«*d87__—vsosess[Cifott-0s-i5——sBanterint.=—SC~—“*‘“—*~*dCS‘“‘<;‘<;<;CS;‘“‘;SSTCCCTC~*Y
`PC~C“‘“c§SSi79ezese[2011-04-12Chiiders
`PSSC*de9=ireeaois[Cipotioat2«idMiche#—C—“—*~—s*~—“—“—‘—‘—*‘idYSC“‘<‘C;CSCSCS””*C<CS:;‘;SSTTTTSTSC~*Y
`
`Paoreariza[izi-06-24Rosenbaum—SC~iC(‘SSCCCCOCOCOCOC™COCCCC*CS
`PpCidz95szg9|2011-06-07[CHFSolutionsinc,|
`pCi967022|006-28Grant
`PSC*d98—*veeiose[Cifotov-i9sangC~—~dSTCCCCOCOCT...CCC‘(CC*d'
`pCi‘8002726|2011-08-23[Karoo
`PCSOBA|00Gura
`
`PS«*d96—‘[sovo7os[Ciot206—séd|ChildersSSSSC—C“—*‘“*dSC“‘CSOCOOOCOC~™COCOCSY
`pCi—sfB0Bo161|2017-12-20Baxter,
`Ppt—C“‘z‘N~=[BO96969|00-17[Roberts
`
`[fsa[ateze7s|—*d2012-05-22=Baxterinternationaling.S|OCC
`
`|SC«*dfoo[stesoas[CorseC—“‘“‘;SCUCdSCOCOCOCOC™C™CTTCVCCCCC“‘(#NNCC*di
`
`STATEMENT BY APPLICANT |examinerName=f
`
`Examiner
`Initial
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/AMM/
`
`Page 2/5
`
`
`
`Receipt date: 11/09/2018
`
`ENE|C000EHeeeerHeya
`
`
`Cite|Publicati Kind|Publicati Nan j re
`
`
`PoEDocument Figures Appear
`
`FOREIGN PATENT DOCUMENTS
`
`FOREIGNPATENTDOCUMENTS
`
`
`
`
`Examiner|Cite|Foreign Doc. |Kind|Publicaiton Nameof Patentee or|Pages, Columns, LinesCountry T
`
`
`
`
`Initial No.|Number Code|DateCode Applicant of cited where Relevant Passages or
`
`Document
`Relevant Figures Appear
`
`Include copy of this form with next communication to applicant.
`
`NON-PATENT LITERATURE DOCUMENTS
`Examiner|Cite|Include name of the author (in CAPITAL LETTERS),title of the article (when appropriate), title of the
`Initial No.|item(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`
`publisher, city and/or country where published.
`
`EXAMINER SIGNATURE
`
`|ExaminerSignature[|sd Date Considered po
`*EXAMINER: Initial if reference considered, whetheror not citation is in conformance with MPEP 609. Drawline through a citation if not in conformance and not considered.
`
`fjAdam Marcetich/
`
`O7/19/2021
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/AMM/
`
`Page 3/5
`
`
`
`Receipt date: 11/09/2018
`
`Attorney Docket Number
`
`|C00017177US01(MED-29176/U
`
`CERTIFICATION STATEMENT
`That each item of information contained in the information disclosure statement wasfirst cited in any communication from a foreign patent office ina
`counterpart foreign application not more than three monthsprior to thefiling of the information disclosure statement. See 37 CFR 1.97(e}(1).
`
`That no item of information contained in the information disclosure statement was cited in a communication from a foreign patentoffice in a
`counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information
`contained in the information disclosure statement was knownto anyindividual designated in 37 CFR 1.56(c) more than three months priorto the filing
`
`of the information disclosure statement. See 37 CFR 1.97(e)(2).
`
`See attachedcertification statement
`A certification statement is not submitted herewith
`
`fs The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`
`SIGNATURE
`Signature[Roger
`
`Registration Number
`
`Fanaa (YY-RINEDD:Name/Print
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/AMM/
`
`Page 4/5
`
`
`
`STATEMENT BY APPLICANT |examinerName=f
`
`C00017177US01(MED-29176/U
`
`Privacy Act Statement
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a
`patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this
`information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by
`the U.S. Patent and TrademarkOffice is to process and/or examine your submission related to a patent application or patent. If you do not furnish the
`requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which mayresult in termination
`of proceedings or abandonmentof the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`Receipt date: 11/09/2018
`
`INFORMATION DISCLOSUREitingDate=| 2018-10-01
`
`aware of a violation or potential violation of law or regulation.
`
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act
`(5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act
`requires disclosure of these record s.
`2. Arecord from this system of records may bedisclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative
`tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a requestinvolving an individual, to whom
`the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
`4. A record in this system of records maybe disclosed, as a routine use, to a contractor of the Agency having needfor the information in order to perform
`a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C.
`552a(m).
`5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use,
`to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C.
`181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an
`inspection of records conducted by GSAaspart of that agency's responsibility to recommend improvements in records managementpractices and
`programs, underauthority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSAregulations governing inspection of
`records for this purpose, and any otherrelevant(i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about
`individuals.
`8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C.
`122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use,
`to the public if the record wasfiled in an application which became abandonedorin which the proceedings were terminated and which application is
`referenced byeither a published application, an application open to public inspections or an issued patent.
`9. A record from this system of records may bedisclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/AMM/
`
`Page 5/5
`
`